HCPCS Level II code Q9982 denotes flutemetamol F18 supplied per study dose (up to 5 millicuries), a diagnostic radiopharmaceutical used in PET imaging to evaluate cerebral beta-amyloid deposition. Nationally, availability and coverage of amyloid PET agents matter for dementia diagnosis pathways, care planning, and downstream utilization of neurologic services and therapeutics.

Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of code intent and clinical context, typical sites of service, and what to look for in payer coverage policies. The publication also highlights common billing considerations and where to find applicable policy language.

This summary provides: an explanation of what Q9982 represents; the clinical role of flutemetamol F18 in PET amyloid imaging; expected places of service; and a guide to the types of benchmarks, policy updates, and clinical context that influence coverage and utilization. Data not available in the input for payer-specific reimbursement benchmarks, associated taxonomies, and ICD-10 linkage is noted where applicable in the full publication.